Journal
CELL REPORTS
Volume 36, Issue 8, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2021.109568
Keywords
-
Categories
Ask authors/readers for more resources
This study demonstrates that drug screening using organoids can identify therapeutic vulnerabilities in MRT and proposes neddylation inhibition as a potential treatment strategy. Mechanistic studies and in vivo experiments confirm the therapeutic efficacy of MLN4924 for MRT, suggesting a new direction for targeted therapy in this aggressive childhood malignancy.
Malignant rhabdoid tumors (MRTs) represent one of the most aggressive childhood malignancies. No effective treatment options are available, and prognosis is, therefore, dismal. Previous studies have demonstrated that tumor organoids capture the heterogeneity of patient tumors and can be used to predict patient response to therapy. Here, we perform drug screening on patient-derived normal and tumor organoids to identify MRT-specific therapeutic vulnerabilities. We identify neddylation inhibitor MLN4924 as a potential therapeutic agent. Mechanistically, we find increased neddylation in MRT organoids and tissues and show that MLN4924 induces a cytotoxic response via upregulation of the unfolded protein response. Lastly, we demonstrate in vivo efficacy in an MRT PDX mouse model, in which single-agent MLN4924 treatment significantly extends survival. Our study demonstrates that organoids can be used to find drugs selectively targeting tumor cells while leaving healthy cells unharmed and proposes neddylation inhibition as a therapeutic strategy in MRT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available